Your browser doesn't support javascript.
loading
Gut Bifidobacteria enrichment following oral Lactobacillus-supplementation is associated with clinical improvements in children with cystic fibrosis.
Ray, Kathryn J; Santee, Clark; McCauley, Kathryn; Panzer, Ariane R; Lynch, Susan V.
Afiliación
  • Ray KJ; Department of Epidemiology and Biostatistics, University of California San Francisco (UCSF), San Francisco, USA.
  • Santee C; Francis I Proctor Foundation, University of California San Francisco (UCSF), San Francisco, USA.
  • McCauley K; Division of Gastroenterology, Department of Medicine, University of California San Francisco (UCSF), 513 Parnassus Ave, S357D, San Francisco, CA, 94143, USA.
  • Panzer AR; Division of Gastroenterology, Department of Medicine, University of California San Francisco (UCSF), 513 Parnassus Ave, S357D, San Francisco, CA, 94143, USA.
  • Lynch SV; Division of Gastroenterology, Department of Medicine, University of California San Francisco (UCSF), 513 Parnassus Ave, S357D, San Francisco, CA, 94143, USA.
BMC Pulm Med ; 22(1): 287, 2022 Jul 28.
Article en En | MEDLINE | ID: mdl-35902830
BACKGROUND: Relationships between gut microbiomes and airway immunity have been established in murine and human studies of allergy and asthma. Early life Lactobacillus supplementation alters the composition and metabolic productivity of the gut microbiome. However, little is known of how Lactobacillus supplementation impacts the gut microbiota in children with cystic fibrosis (CF) and whether specific microbiota states that arise following gut microbiome manipulation relate to pulmonary outcomes. METHODS: Stool samples were collected from CF patients enrolled in a multi-center, double-blind, randomized placebo-controlled trial of daily Lactobacillus rhamnosus strain GG (LGG) probiotic supplementation over a 12-month period. Fecal 16S rRNA biomarker sequencing was used to profile fecal bacterial microbiota and analyses were performed in QiiME. RESULTS: Bifidobacteria-dominated fecal microbiota were more likely to arise in LGG-treated children with CF (P = 0.04). Children with Bifidobacteria-dominated gut microbiota had a reduced rate of pulmonary exacerbations (IRR = 0.55; 95% CI 0.25 to 0.82; P = 0.01), improved pulmonary function (+ 20.00% of predicted value FEV1; 95% CI 8.05 to 31.92; P = 0.001), lower intestinal inflammation (Calprotectin; Coef = - 16.53 µg g-1 feces; 95% CI - 26.80 to - 6.26; P = 0.002) and required fewer antibiotics (IRR = 0.43; 95% CI 0.22 to 0.69; P = 0.04) compared to children with Bacteroides-dominated microbiota who were less likely to have received LGG. CONCLUSIONS: The majority of pediatric CF patients in this study possessed a Bacteroides- or Bifidobacteria-dominated gut microbiota. Bifidobacteria-dominated gut microbiota were more likely to be associated with LGG-supplementation and with better clinical outcomes.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Probióticos / Fibrosis Quística / Lacticaseibacillus rhamnosus Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Animals / Child / Humans Idioma: En Revista: BMC Pulm Med Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Probióticos / Fibrosis Quística / Lacticaseibacillus rhamnosus Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Animals / Child / Humans Idioma: En Revista: BMC Pulm Med Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido